Serina Therapeutics
Manufacturing · Alabama, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
601 Genome Way Ste 2001, Huntsville, Ala...Phone Number
(256) 327-9630Website
www.serinatx.comRevenue
<$5 MillionStock Symbol
SERIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.Explore more
Serina Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Serina Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Serina Therapeutics has new funding data
Serina Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Serina Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Serina Therapeutics
Check if Serina Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Serina Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Serina Therapeutics is spiking on competitors!
Product Launch: Get notified when Serina Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Serina Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Serina Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Serina Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Serina Therapeutics.
Serina Therapeutics financials insights
Gather financial insights about Serina Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$4.9M
2017
Private Equity
$8M
2020
Debt
$150K
2022
Series B
$5M
2024
Private Equity
$10M
2025
Share Placement
$5M
Stock/Share Issuance
$20M
2026
Stock/Share Issuance
$30M
Serina Therapeutics Tech Stack
A closer look at the technologies used by Serina Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
Funding
Serina Therapeutics has secured $30 million in Share Issuance funding. Investors were not disclosed.
Funding
Person-Based
Person-Based
Serina Therapeutics News & Media
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective immediately. Dr. Simon will also serve on the Board's Audit and Compensation Committees.Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
HUNTSVILLE, Ala., July 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease.Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology.Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 -
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Serina Therapeutics
Sign Up For FreeTo access detailed company insights
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid... Read More
